Business & regional news

Confirmation comes from the position paper published by the Italian Society of Nephrology (SIN), expanding the indication of RDN to a complex and high-risk patient population

Recognition highlights Medtronic design excellence and commitment to improving patient lives

Medtronic also announced completion of enrollment in SPYRAL AFFIRM, which aims to build robust real-world evidence across traditionally underserved patient populations

Stedi Extra Support Guidewire Delivers Enhanced Support for Stability, Safety, and Predictability During Valve Deployment for Aortic Stenosis

Partnership launches AI solution to enhance predictive heart valve visualization and personalize valve treatment planning decisions enabling the future of TAVR for structural heart patients

Avalus Ultra valve expands Medtronic Cardiac Surgery’s portfolio of
cardiac surgical innovations

With this labeling approval, Medtronic continues to lead the way in advancing aortic care with clinical evidence for the treatment of ruptured abdominal aortic aneurysms (rAAA). Medtronic plc, a...

Findings highlight the potential of new investigational waveforms for the all-in-one mapping and dual-energy ablation system in advancing treatment for ventricular arrhythmia patients

Backed by exceptional clinical outcomes, the Neuroguard IEP™ System’s unique 3-in-1 design provides enhanced embolic protection when it matters most.1-5, † Medtronic, a global leader in...

New VitalFlow system expands Medtronic Cardiac Surgery’s portfolio globally

Medtronic expands its cardiac surgery portfolio with the European launch of the Penditure LAA Exclusion System

Dr. Arthur brings more than 20 years of experience as a practicing neurosurgeon and a commitment to innovation, patient safety, and improving stroke care outcomes

London office expansion underlines Medtronic’s commitment to fostering cross-industry collaboration, contributing to ambitions of the NHS 10-Year Health Plan and driving surgical innovation.

The pivotal Medtronic Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) trial demonstrates global clinical effectiveness, long-term safety, and patient preference

After three years, most insulin was delivered automatically by the system, and those who used the recommended optimal settings experienced the greatest benefits.